A Phase I dose-escalating and safety study of AZD8931 in combination with Oxaliplatin and Capecitabine chemotherapy in patients with Oesophago-gastric adenocarcinoma.

Trial Profile

A Phase I dose-escalating and safety study of AZD8931 in combination with Oxaliplatin and Capecitabine chemotherapy in patients with Oesophago-gastric adenocarcinoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 03 May 2017

At a glance

  • Drugs Sapitinib (Primary) ; Capecitabine; Oxaliplatin
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Acronyms DEBIOC
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 May 2017 Status changed from active, no longer recruiting to completed.
    • 02 Jul 2016 Status changed from recruiting to completed.
    • 23 Feb 2016 Planned End Date changed from 31 Jan 2016 to 29 Feb 2016 as reported by United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top